Previous 10 | Next 10 |
Announces Positive Results in ONSET-2 Phase 3 Trial of OC-01 Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease ONSET-2 Data Enables NDA Submission in 2H 2020 Cash and Cash Equivalents of $128.6 million as of March 31, 2020 Conference Call and Webcast S...
PRINCETON, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced tha...
Gainers: RTIX +50.0% . QTNT +19.6% . SNDX +17.3% . PI +9.2% . More news on: RTI Surgical Holdings, Inc., Quotient Limited, Syndax Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020 NDA Submission Expected During 2H 2020 PRINCETON, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stag...
Today, we will see why Oyster Point Pharma ( OYST ) is an attractive investment opportunity in 2020. Company overview Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative treatments targeting ocular surface disea...
Image source: The Motley Fool. Oyster Point Pharma (NASDAQ: OYST) Q4 2019 Earnings Call Feb 27, 2020 , 4:30 p.m. ET Operator Continue reading
Oyster Point Pharma (NASDAQ: OYST ): GAAP EPS of -$1.41 misses by $0.75 . More news on: Oyster Point Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020 Cash and Cash Equivalents of $139.1 million as of December 31, 2019 Conference Call and Webcast Scheduled for 4:30 pm ET PRINCETON, N.J., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinic...
PRINCETON, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced that Jef...
News, Short Squeeze, Breakout and More Instantly...
Oyster Point Pharma Inc. Company Name:
OYST Stock Symbol:
NASDAQ Market:
Oyster Point Pharma Inc. Website:
TYRVAYA ® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3 ’ 22 Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately 6,100 Unique Eye Care Profes...
Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”), ...